Provided by Tiger Trade Technology Pte. Ltd.

Pulmatrix

1.36
-0.1500-9.93%
Post-market: 1.400.0400+2.94%17:28 EDT
Volume:145.23K
Turnover:206.33K
Market Cap:4.97M
PE:-0.96
High:1.46
Open:1.42
Low:1.32
Close:1.51
52wk High:9.37
52wk Low:1.32
Shares:3.65M
Float Shares:3.63M
Volume Ratio:0.78
T/O Rate:4.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4100
EPS(LYR):-1.4134
ROE:-80.93%
ROA:-45.88%
PB:1.30
PE(LYR):-0.96

Loading ...

Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq

TIPRANKS
·
Yesterday

Pulmatrix agrees to acquire Eos SENOLYTIX; $19 million financing grows to advance PTC-2105 program

Reuters
·
Mar 26

Pulmatrix Inc - Upon Completion of Merger, Combined Company Will Operate as Eos Senolytix, Inc

THOMSON REUTERS
·
Mar 26

Pulmatrix Inc: $19 Mln Financings to Advance Lead Clinical Candidate PTC-2105 for Sarcopenia and Age-Related Disease

THOMSON REUTERS
·
Mar 26

Pulmatrix Inc - Combined Company Expected to Trade on Nasdaq Under Ticker Symbol "Eosx."

THOMSON REUTERS
·
Mar 26

Press Release: Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Dow Jones
·
Mar 26

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:59 AM

Reuters
·
Mar 26

Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix

Dow Jones
·
Mar 02

Pulmatrix Inc - Advances Discussions on Alternative Merger Opportunities

THOMSON REUTERS
·
Mar 02

Press Release: Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Dow Jones
·
Mar 02

Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY

Benzinga
·
Feb 26

Pulmatrix FY 2025 net loss USD 5.2 million -46%

Reuters
·
Feb 26

Press Release: Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Dow Jones
·
Feb 26

BRIEF-Pulmatrix And Cullgen Continue To Pursue Merger

Reuters
·
Dec 18, 2025

Pulmatrix and Cullgen Waive No-Solicitation Clause to Explore Alternatives Amid Ongoing Merger Approval Process

Reuters
·
Dec 18, 2025

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

THOMSON REUTERS
·
Dec 18, 2025

Pulmatrix Inc - Co and Cullgen Waive "No Solicitation" Clause in Merger Agreement

THOMSON REUTERS
·
Dec 18, 2025

Pulmatrix Reports Q3 2025 Results and Strategic Shift

TIPRANKS
·
Oct 17, 2025

Pulmatrix reports Q3 EPS (24c) vs. (71c) last year

TIPRANKS
·
Oct 16, 2025

Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment

Reuters
·
Oct 16, 2025